Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
Edwards Lifesciences (EW) PT Raised to $135 at Oppenheimer
December 9, 2021 6:31 AM ESTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $122.00) while maintaining an Outperform rating following the company's Analyst Day.
The analyst commented, "Edwards hosted its annual analyst day yesterday (12/8). Investors focused on developments in TMTT, especially... More
Edwards Lifesciences (EW) PT Raised to $132 at Stifel Following Analyst Day
December 9, 2021 6:12 AM ESTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $132.00 (from $129.00) while maintaining a Buy rating following the company's Analyst Day which underscores the key pipeline opportunities driving top-tier growth outlook for next year and beyond.
The analyst commented,... More
Edwards Lifesciences (EW) PT Raised to $140 at Cowen; Named Best 2022 Idea
December 9, 2021 5:49 AM ESTCowen analyst Joshua Jennings raised the price target on Edwards Lifesciences (NYSE: EW) to $140.00 (from $125.00) while maintaining an Outperform rating and named the stock a Best Idea for 2022.
The analyst commented, "EW's investor day featured favorable business updates, a reiteration of '21 guidance... More



